Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)
| Fund Assets | 676.00M |
| Expense Ratio | 0.80% |
| Min. Investment | $1,000 |
| Turnover | 35.87% |
| Dividend (ttm) | 11.76 |
| Dividend Yield | 9.28% |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 20, 2024 |
| Previous Close | 122.90 |
| YTD Return | -0.10% |
| 1-Year Return | -4.51% |
| 5-Year Return | -8.51% |
| 52-Week Low | 104.73 |
| 52-Week High | 160.08 |
| Beta (5Y) | n/a |
| Holdings | 88 |
| Inception Date | Sep 1, 2009 |
About FTDZX
Franklin Biotechnology Discovery Fund Advisor Class is a mutual fund that focuses on delivering capital appreciation by investing primarily in the biotechnology sector. Under normal market conditions, the fund allocates at least 80% of its net assets to equity securities of biotechnology companies and discovery research firms—enterprises that derive a significant portion of their revenue from biotechnology-related activities. The fund’s portfolio often includes both established and emerging biotechnology firms, with a notable allocation to smaller capitalization companies, typically those with market values below $2 billion at the time of investment. While the fund maintains a majority exposure to U.S.-based companies, it may allocate up to 20% of its assets to foreign securities, including American, European, and Global Depositary Receipts. Managed using a fundamental, research-driven investment approach, the fund seeks out companies with identifiable drivers of future earnings growth and sustainable growth characteristics. Franklin Biotechnology Discovery Fund Advisor Class plays a significant role in offering investors a specialized vehicle for gaining exposure to innovations and growth opportunities within the global biotechnology industry, reflecting both the sector’s risk profile and potential for long-term growth.
Performance
FTDZX had a total return of -4.51% in the past year, including dividends. Since the fund's inception, the average annual return has been 10.07%.
Top 10 Holdings
49.47% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 8.17% |
| Amgen Inc. | AMGN | 7.64% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.25% |
| Ascendis Pharma A/S | ASND | 4.89% |
| Regeneron Pharmaceuticals, Inc. | REGN | 4.34% |
| argenx SE | ARGX | 3.80% |
| Jazz Pharmaceuticals plc | JAZZ | 3.79% |
| Merus N.V. | MRUS | 3.52% |
| PTC Therapeutics, Inc. | PTCT | 3.16% |
| Neurocrine Biosciences, Inc. | NBIX | 2.91% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2024 | $11.7607 | Dec 20, 2024 |
| Dec 20, 2022 | $0.4163 | Dec 20, 2022 |
| Dec 15, 2021 | $18.0843 | Dec 15, 2021 |
| Dec 15, 2020 | $10.3921 | Dec 15, 2020 |
| Dec 16, 2019 | $14.1643 | Dec 18, 2019 |
| Dec 17, 2018 | $4.5496 | Dec 19, 2018 |